Caregivers' assessment of meaningful and relevant clinical outcome assessments for Sanfilippo syndrome

Katherine Ackerman Porter; Cara O'Neill; Elise Drake; Sara M Andrews; Kathleen Delaney; Samantha Parker; Maria L Escolar; Stacey Montgomery; William Moon; Carolyn Worrall; Holly L Peay

doi:10.1186/s41687-022-00447-w

Caregivers' assessment of meaningful and relevant clinical outcome assessments for Sanfilippo syndrome

J Patient Rep Outcomes. 2022 Apr 25;6(1):40. doi: 10.1186/s41687-022-00447-w.

Authors

Affiliations

¹ Center for Genomics, Bioinformatics, and Translational Research, RTI International, Research Triangle Park, NC, USA.
² Cure Sanfilippo Foundation, Columbia, SC, USA.
³ Global Patient Advocacy and Engagement, BioMarin Pharmaceutical Inc., San Rafael, CA, USA.
⁴ Patient and Policy Affairs, Lysogene, Neuilly sur Seine, France.
⁵ Department of Pediatrics, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
⁶ Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA, USA.
⁷ Cure Sanfilippo Foundation Parent Advocates, Columbia, SC, USA.
⁸ Center for Genomics, Bioinformatics, and Translational Research, RTI International, Research Triangle Park, NC, USA. hpeay@rti.org.

Abstract

Objectives: Sanfilippo syndrome is a rare multisystem disease with no approved treatments. This study explores caregiver perspectives on the most impactful symptoms and patient-relevant clinical outcomes assessments. The pediatric onset and progressive neurodegenerative nature of Sanfilippo limits use of self-report in clinical research. This study obtains Sanfilippo caregiver data to support the selection of fit-for-purpose and patient-relevant clinical outcome assessments (COAs).

Methods: We conducted an asynchronous online focus group (n = 11) followed by individual interviews with caregivers (n = 19) of children with Sanfilippo syndrome. All participants reported on the impact of disease symptoms and level of unmet treatment need across Sanfilippo symptom domains. Focus group participants reviewed existing assessments relating to 8 symptom domains (15 total assessments) and provided feedback on meaningfulness and relevance. Focus group data were used to reduce the number of assessments included in subsequent interviews to 8 COAs across 7 symptom domains: communication, eating, sleep, mobility, pain, behavior and adapting. Interview respondents provided data on meaningfulness and relevance of assessments. Data were coded using an item-tracking matrix. Data summaries were analyzed by caregivers' responses regarding meaningfulness; relevance to Sanfilippo syndrome; and based on caregiver indication of missing or problematic subdomains and items.

Results: Participants' children were 2-24 years in age and varied in disease progression. Caregivers reported communication and mobility as highly impactful domains with unmet treatment needs, followed closely by pain and sleep. Domains such as eating, adaptive skills, and behaviors were identified as impactful but with relatively less priority, by comparison. Participants endorsed the relevance of clinical outcome assessments associated with communication, eating, sleep, and pain, and identified them as highly favorable for use in a clinical trial. Participants specified some refinements in existing assessments to best reflect Sanfilippo symptoms and disease course.

Discussion: The identification of impactful symptoms to treat and relevant and meaningful clinical outcome assessments supports patient-focused drug development. Our results inform targets for drug development and the selection of primary and secondary outcome assessments with high meaningfulness and face validity to Sanfilippo syndrome caregivers. Assessments identified as less optimal might be refined, replaced, or remain if the clinical trial necessitates.